Jun 15, 2020

Why Novo Nordisk is buying biotech firm Corvidia

Health
diabetes
Cardiovascular
Biotech
William Smith
2 min
Danish pharmaceutical multinational Novo Nordisk has announced it is to acquire the Massachusetts-based Corvidia Therapeutics
Danish pharmaceutical multinational Novo Nordisk has announced it is to acquire the Massachusetts-based Corvidia Therapeutics...

Danish pharmaceutical multinational Novo Nordisk has announced it is to acquire the Massachusetts-based Corvidia Therapeutics.

Novo Nordisk specialises in diabetes medications, while Corvidia is a clinical-stage company focused on R&D for cardio-renal diseases.

Novo Nordisk said its interest was spurred by a desire to expand its capabilities for cardiovascular disease, which is linked to its core business of diabetes and obesity. The relationship between obesity and cardiovascular disease is well documented, with the ongoing COVID-19 epidemic bringing a renewed focus on the increased risks to health caused by obesity in general.

Corvidia is developing a pharmaceutical known as ziltivekimab to reduce the risk of heart attacks in those suffering from chronic kidney disease. The medication is currently being evaluated in medical trials.

In a press release, Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: “We believe that ziltivekimab has the potential to become a first- and best-in-class treatment to lower the burden of cardiovascular disease in a patient population that is at high risk of major adverse cardiovascular events.”

Novo Nordisk said that under the terms of the agreement, it would acquire all of Corvidia’s outstanding shares for $725mn, but that total payments could amount to $2.1bn pursuant to regulatory and sales milestones.

”This acquisition recognises the important scientific work Corvidia has been doing over the last five years in cardio-renal diseases with a focus on inflammation,” said Marc de Garidel, chief executive officer of Corvidia Therapeutics. “In Novo Nordisk, we have found a partner that has deep expertise in cardiometabolic disease, a proven track record of success in conducting cardiovascular outcomes trials (CVOT), and the infrastructure to accelerate the development of ziltivekimab in order to help patients who need it most.”

The deal remains subject to the end of a waiting period and other usual conditions.

Share article

Jun 15, 2021

 NHS trials test that predicts sepsis 3 days in advance 

sepsis
MachineLearning
clinicaltrial
blooddisorder
2 min
Queen Alexandra Hospital is trialling a new sepsis test by Presymptom Health that uses machine learning to detect the onset of the disease

A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England. 

Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year. 

The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time. 

From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.

Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction. 

Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.

The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years. 

If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.

Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”

Share article